- Home
- SLP vs ACRS Comparison
SLP vs ACRS Comparison
Compare SLP & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLP | ACRS |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.4M | 314.2M |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SLP | ACRS |
|---|---|---|
| Price | $19.18 | $3.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $27.25 | $9.75 |
| AVG Volume (30 Days) | 336.7K | ★ 1.3M |
| Earning Date | 01-08-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,179,000.00 | $15,742,000.00 |
| Revenue This Year | $2.02 | N/A |
| Revenue Next Year | $6.92 | $6.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.09 | N/A |
| 52 Week Low | $12.39 | $1.05 |
| 52 Week High | $37.67 | $3.48 |
Technical Indicators
Market Signals| Indicator | SLP | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 54.70 |
| Support Level | $17.74 | $2.78 |
| Resistance Level | $19.62 | $3.23 |
| Average True Range (ATR) | 0.72 | 0.20 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 53.23 | 37.41 |
Price Performance
Historical ComparisonAbout SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.